Intercept Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Intercept Pharmaceuticals generated cash of -$26,780,000, which is more than the previous year. Cash used in financing activities reached the amount of -$267,316,000 last year. Net change in cash is therefore -$38,549,000.
Cash Flow
| 2013 | -28.00M | -70.21M | 66.07M |
|---|---|---|---|
| 2014 | -87.73M | -96.58M | 190.98M |
| 2015 | -162.90M | -389.47M | 565.46M |
| 2016 | -342.44M | -60.13M | 414.38M |
| 2017 | -265.40M | 287.77M | 2.83M |
| 2018 | -240.71M | -48.07M | 263.54M |
| 2019 | -236.61M | -188.98M | 457.51M |
| 2020 | -170.02M | 162.81M | -693K |
| 2021 | -41.63M | 70.72M | 1.11M |
| 2022 | -26.78M | 261.84M | -267.31M |
ICPT Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 94.40M | 65.65M | 74.78M | 43.24M | 70.01M | 43.67M | 32.74M | 20.02M | 13.36M | 45.51M |
Operating activities | ||||||||||
Net income | -174.85M | -91.42M | -274.88M | -344.68M | -309.24M | -360.36M | -412.83M | -226.42M | -283.22M | -67.79M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 592K | 2.97M | 3.11M | 3.66M | 4.58M | 4.60M | 3.83M | 1.69M | 442.79K | 105.68K |
Stock-based compensation expense | 21.88M | 33.88M | 60.85M | 55.98M | 49.91M | 56.96M | 46.20M | 34.18M | 20.12M | 9.44M |
| Deferred income tax benefit | 21.88M | 33.88M | 60.85M | 55.98M | 49.91M | 56.96M | 46.20M | 34.18M | 20.12M | 9.44M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 1.47M | -7.14M | -2.64M | -12.35M | -9.19M | -7.37M | -9.12M | 0 | 0 | 0 |
Inventories | 602K | 231K | -269K | -1.35M | -3.62M | -1.20M | -2.27M | 0 | 0 | 0 |
Accounts payable | 23.28M | -4.82M | 13.86M | 56.41M | 10.33M | 29.22M | 19.96M | 32.21M | 6.19M | 3.51M |
Cash generated by operating activities | -26.78M | -41.63M | -170.02M | -236.61M | -240.71M | -265.40M | -342.44M | -162.90M | -87.73M | -28.00M |
Investing activities | ||||||||||
Purchases Of Investments | -552.73M | -349.45M | -330.71M | -603.01M | -436.07M | -231.10M | -511.52M | -640.70M | -204.34M | -125.82M |
Investments In Property Plant And Equipment | -568K | -397K | -3.89M | -1.13M | -167K | -10.39M | -5.07M | -5.93M | -4.64M | -1.62M |
Acquisitions Net | 0 | -71.12M | -166.70M | 187.85M | 0 | 0 | 0 | 0 | 0 | 1.62B |
Cash generated by investing activities | 261.84M | 70.72M | 162.81M | -188.98M | -48.07M | 287.77M | -60.13M | -389.47M | -96.58M | -70.21M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 0 | 227.26M | 261.36M | 0 | 0 | 0 | 0 | 61.16M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -557K | -75.82M | -1.99M | -2.15M | -2.18M | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -38.12M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | -267.31M | 1.11M | -693K | 457.51M | 263.54M | 2.83M | 414.38M | 565.46M | 190.98M | 66.07M |
Net Change In Cash | -38.54M | 28.75M | -9.12M | 31.53M | -26.76M | 26.33M | 10.93M | 12.71M | 6.65M | -32.14M |
Cash at end of period | 55.86M | 94.40M | 65.65M | 74.78M | 43.24M | 70.01M | 43.67M | 32.74M | 20.02M | 13.36M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |